Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN4 | P29074 | 1/20 | 0.37 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 3/20 | 0.37 |
| ▸ | ANPEP | P15144 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31590359 | 0.75 | HPGD (0.46) | HPGDPTPN2PTPN1PTPN4PTPN9 | |
| SCHEMBL3894225 | 0.72 | GABBR1 (1.00) | GABBR1GABRR1TSHR | |
| SCHEMBL3897695 | 0.72 | GABBR1 (1.00) | GABBR1GABRR1TSHR | |
| SCHEMBL3894140 | 0.72 | GABBR1 (0.60) | GABBR1GABRR1 | |
| SCHEMBL3898177 | 0.72 | GABBR1 (0.60) | GABBR1GABRR1 | |
| SCHEMBL31590204 | 0.70 | HPGD (0.41) | HPGDPTPN2PTPN1PTPN4PTPN9 | |
| SCHEMBL6448091 | 0.68 | CFTR (0.64) | HPGDPTPN2PTPN1PTPN4PTPN9 | |
| SCHEMBL1764685 | 0.66 | HPGD (0.56) | HPGDLAP3ANPEPTSHRERAP1 | |
| Benzylphosphonic Acid SCHEMBL44318 | 0.65 | HPGD (0.60) | HPGDLAP3ANPEPTSHRERAP1 | |
| SCHEMBL497159 | 0.65 | HPGD (0.60) | HPGDLAP3ANPEPTSHRERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773740-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2009-02-18 | — | — | EP | disclosed |
| US-20080032950-A1 | Neurologically-Active Compounds | THE UNIVERSITY OF SYDNEY (AU) | 2008-02-07 | — | — | US | disclosed |
| EP-1773740-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2007-09-19 | — | — | EP | disclosed |
| EP-1773740-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006000043-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032950-A1 | Neurologically-Active Compounds | GABRE, GABRA5, GABRA1 | GABBR1 20/4885HPGD 2362/4885GABRR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.